Pakistan Medicine Import 2026 Market Overview & Trends

Pakistan's pharmaceutical imports peaked in 2022 at $485 million. However, a significant shift occurred in 2023, where import value dropped to $350 million while quantity spiked to 19.5 million units. By 2024, the market showed signs of value recovery reaching $369 million, suggesting a stabilization in pricing and demand compared to the previous year's volatility.

In 2024, Germany emerged as the leading exporter of medicine to Pakistan, totaling $58.7 million. It is followed by Switzerland ($45.4M) and India ($43.6M). The presence of Italy and France in the top five highlights a strong preference for European pharmaceutical standards, alongside significant regional supply from India.

India is the most rapidly emerging partner, showcasing a massive 81.8% growth rate in 2024. France and Austria also demonstrate strong momentum with growth rates of 34.1% and 30.2% respectively. Even established partners like Germany and China continue to grow at double-digit rates, indicating a diversifying and competitive supplier landscape.

The import market is heavily concentrated in therapeutic medicaments (HS 300490), which accounted for $276.4 million in 2024. Insulin represents the second-largest category at $55.1 million. Other essential categories include hormones and antibiotics, reflecting a high dependency on imported solutions for chronic conditions and infectious disease management.